https://www.selleckchem.com/pr....oducts/apr-246-prima
Further randomized trials investigate the benefit of antibodies and immune checkpoint inhibitors in locoregional and advanced metastatic gastric cancer with promising results. The results of the ongoing randomized trials will show if oligometastatic patients benefit from a multimodal treatment with resection. The clear definition of the oligometastatic state, assessment of the response to neoadjuvant chemotherapy and realistic estimation of the R0resectability will be useful for patient selection. The results of the ongoing r
Beğen
Yorum Yap
Paylaş
